Eli Lilly and Company (NYSE:LLY) Shares Bought by Gofen & Glossberg LLC IL
Gofen & Glossberg LLC IL raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.2% during the first quarter, Holdings Channel reports. The institutional investor owned 24,092 shares of the company’s stock after buying an additional 510 shares during the period. Gofen & Glossberg LLC IL’s holdings in Eli Lilly and were worth $2,026,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of the stock. Verde Servicos Internacionais S.A. acquired a new stake in Eli Lilly and during the first quarter valued at about $10,598,000. TNB Financial acquired a new stake in Eli Lilly and during the first quarter valued at about $430,000. Bremer Trust National Association raised its stake in Eli Lilly and by 2.2% in the first quarter. Bremer Trust National Association now owns 3,336 shares of the company’s stock valued at $281,000 after buying an additional 71 shares in the last quarter. Beutel Goodman & Co Ltd. acquired a new stake in Eli Lilly and during the first quarter valued at about $161,084,000. Finally, CrestPoint Capital Management LLC raised its stake in Eli Lilly and by 320.7% in the first quarter. CrestPoint Capital Management LLC now owns 12,200 shares of the company’s stock valued at $1,026,000 after buying an additional 9,300 shares in the last quarter. 75.61% of the stock is owned by institutional investors.
Eli Lilly and Company (NYSE:LLY) opened at 82.00 on Monday. The stock has a market cap of $86.51 billion, a P/E ratio of 35.48 and a beta of 0.34. The company’s 50-day moving average price is $82.99 and its 200-day moving average price is $81.53. Eli Lilly and Company has a one year low of $64.18 and a one year high of $86.72.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same period in the prior year, the company posted $0.86 EPS. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. Analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.53%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is currently 90.04%.
Several equities research analysts recently issued reports on the company. Zacks Investment Research raised Eli Lilly and from a “hold” rating to a “buy” rating and set a $96.00 price objective for the company in a research note on Wednesday, April 12th. Cowen and Company raised their price target on Eli Lilly and from $85.00 to $95.00 and gave the company an “outperform” rating in a research report on Monday, April 17th. Morgan Stanley downgraded Eli Lilly and from an “overweight” rating to an “equal weight” rating and set a $82.00 price target on the stock. in a research report on Monday, April 17th. Piper Jaffray Companies restated a “buy” rating and set a $100.00 price target on shares of Eli Lilly and in a research report on Monday, April 17th. Finally, BMO Capital Markets downgraded Eli Lilly and from a “market perform” rating to an “underperform” rating and lowered their price target for the company from $73.00 to $71.00 in a research report on Monday, April 17th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the stock. Eli Lilly and presently has an average rating of “Hold” and a consensus price target of $88.27.
In related news, VP Michael J. Harrington sold 22,833 shares of the stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $79.97, for a total value of $1,825,955.01. Following the sale, the vice president now directly owns 62,056 shares of the company’s stock, valued at approximately $4,962,618.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of the stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the completion of the sale, the insider now directly owns 124,049,283 shares in the company, valued at $10,307,254,924.47. The disclosure for this sale can be found here. Insiders sold a total of 669,733 shares of company stock worth $55,845,287 over the last three months. 0.20% of the stock is currently owned by corporate insiders.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.